Peer-reviewed veterinary case report
MicroRNA levels in spinal fluid of Great Danes with neck disease
By Vansteenkiste, Daniella P et al.·Published in Journal of veterinary internal medicine·2019·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: MicroRNA expression in the cerebrospinal fluid of dogs with and without cervical spondylomyelopathy.
- Species:
- dog
Plain-English summary
A group of Great Danes with cervical spondylomyelopathy (a condition affecting the neck and spine) had their cerebrospinal fluid tested to look for specific microRNAs that might indicate the disease. Researchers found that two microRNAs, miR-494 and miR-612, showed different levels in the fluid of affected dogs compared to healthy ones. While miR-494 was more abundant in dogs with the condition, miR-612 was less so. This study suggests that these microRNAs could potentially help in diagnosing cervical spondylomyelopathy in dogs, but further research is needed to confirm their usefulness.
People also search for: Great Dane neck pain · cervical spondylomyelopathy in dogs · dog cerebrospinal fluid test
Abstract
BACKGROUND: Osseous-associated cervical spondylomyelopathy (OA-CSM) is a common condition of the cervical vertebral column that affects giant dog breeds. MicroRNAs (miRNAs) are small RNAs that regulate gene expression, and recent data suggest that circulating miRNAs present in biological fluids may serve as potential biomarkers for disease. The miRNA profiles of cerebrospinal fluid (CSF) from healthy dogs and dogs clinically affected by OA-CSM have not been described. OBJECTIVE: To characterize the expression levels of miRNAs present in the CSF of normal Great Danes and identify differentially expressed miRNAs in the CSF of Great Danes clinically affected with OA-CSM. ANIMALS: Client-owned dogs: 12 control, 12 OA-CSM affected. METHODS: Cerebrospinal fluid samples were collected prospectively. MicroRNA expression was evaluated using the NanoString nCounter platform and quantitative real-time PCR. RESULTS: We identified 8 miRNAs with significant differential expression. MiR-299-5p and miR-765 had increased expression levels in the CSF of OA-CSM-affected dogs, whereas miR-494, miR-612, miR-302-d, miR-4531, miR-4455, and miR-6721-5p had decreased expression levels in OA-CSM affected dogs compared to clinically normal dogs. Quantitative real-time PCR was performed to validate the expression levels of 2 miRNAs (miR-494 and miR-612), and we found a 1.5-fold increase in miR-494 expression and a 1.2-fold decrease in miR-612 in the CSF of the OA-CSM affected group (P = .41 and .89, respectively). CONCLUSIONS AND CLINICAL IMPORTANCE: Data generated from our study represent an initial characterization of the miRNA profile of normal canine CSF and suggest that a distinct CSF miRNA expression profile is associated with OA-CSM.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31639228/